Menu

Mining Spider Toxins for Analgesic Clues

Arachnids harbor a plentiful array of molecules that target mammalian pain receptors.

Jan 1, 2018
Catherine Offord

BASTIAN RAST

Comprising more than 40,000 species—almost all of which produce venom—spiders are a treasure trove of nerve-attacking molecules. “They’re basically little combinatorial peptide libraries walking around on a bunch of legs,” says David Julius, a physiologist at the University of California, San Francisco. “They’ve had millions of years to evolve peptide sequences that interact with the functionally most important parts of protein targets.”

Those targets are often ion channels in the membranes of pain-sensing neurons. In a recent screen of multiple venoms, Julius’s group identified two toxins from the Togo starburst tarantula (Heteroscodra maculata) that selectively activated the mammalian voltage-gated sodium channel NaV1.1, which behavioral experiments with mice revealed plays a previously unknown role in mechanical pain (Nature, 534:494-99, 2016). The team also characterized one of the toxin’s binding sites, opening a route to developing selective NaV1.1 inhibitors for analgesia.

See “David Julius Probes the Molecular Mechanics of Pain

Other toxins inhibit, rather than activate, these channels, providing more-direct inspiration for analgesic drug design. In 2017, a group of researchers in Australia reported that Pn3a—a peptide from the giant blue bloom tarantula (Pamphobeteus nigricolor)—inhibits the pain-associated sodium channel NaV1.7 by binding to its voltage-sensing domains, and is analgesic in rodents when administered with subtherapeutic levels of opioids (Sci Rep, 7:40883). The same group recently identified another NaV1.7 inhibitor, Cd1a, from the African rear-horned baboon spider (Ceratogyrus darlingi).

The specificity of such toxins is appealing to industry, notes Lachlan Rash, a pharmacologist at the University of Queensland. Pfizer researchers recently synthesized NaV1.7-targeting “microproteins” inspired by peptides from the straight-horned baboon tarantula (Ceratogyrus marshalli). And last year, Janssen scientists engineered a variant of protoxin II, originally isolated from Peruvian green velvet tarantula (Thrixopelma pruriens) venom, that made rats insensitive to pain by blocking NaV1.7 activation (Sci Rep, 7:39662, 2017).

Spider venoms are “really showing us pathways that we can target,” explains Rash. Then, “we can try and mimic them with molecules that might have more-favorable pharmacokinetic properties, or be easier and cheaper to manufacture.” 

Read about other animal groups researchers are exploring for pain-killing leads in the full feature story, “Animal Analgesics.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.